Of the three, the drug manufactured by Stellapharm Vietnamhas been approved for clinical trial. Because Molnupiravir has yet been grantedwith a circulation registration number in Vietnam, the Ministry of Health isconsidering asking the Government for approval of using the drug inemergency cases. If approved by the Government, it is expected that three registrationnumbers will be issued for three types of Molnupiravir drugs manufactured by domesticpharmaceutical companies.
Regarding the effectiveness of Molnupiravir on COVID-19 patients in Vietnam,the Department of Science, Technology and Training under the Ministry of Healthsaid that from the end of August, the ministry has piloted using Molnupiravirfor non-hospitalised patients. Ho Chi Minh City was the first locality to implementthis pilot programme. At present, it has been arried out in 34 provinces andcities.
The ministry has provided 110,000 doses, including 50,000doses of Molnupiravir 400 mg Stella VN, and 60,000 doses of Molnupiravir 200 mgOptimus produced by India to localities.
The use of the drug in 22 provinces and cities showthat Molnupiravir is safe and well-accepted, and has obvious effectiveness inreducing viral load, virus spread and the number of severe cases, andshortening treatment time, with no fatalities recorded.
Molnupiravir is developed by the US-based pharmaceuticalcompanies Ridgeback Biotherapeutics and Merck & Co., Inc./.